Stephen Chen, MD
Critical Care Medicine · Monterey Park, CANPI 1205821477
Payments from drug & device makers
Across 832 payments — averaging $473.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$216K
- AstraZeneca$105K
- Boehringer Ingelheim$29K
- Mylan Specialty L.p.$12K
- Bayer$11K
- AbbVie$10K
- plus $10K from 33 others
What the payments were for
- Consulting fees$12,3793%
- Speaking & faculty fees$348,51089%
- Travel & lodging$6,5592%
- Food & beverage$25,3836%
- Education$7930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 247 | $216,453 |
| AstraZeneca | 176 | $105,032 |
| Boehringer Ingelheim | 79 | $28,968 |
| Mylan Specialty L.p. | 44 | $12,436 |
| Bayer | 19 | $11,225 |
| AbbVie(2 entities) | 69 | $9,971 |
| Verona Pharma, Inc. | 15 | $2,715 |
| Viatris Specialty LLC | 5 | $1,437 |
| Merck | 34 | $999 |
| Actelion Pharmaceuticals US, Inc. | 20 | $841 |
| Genentech USA, Inc. | 31 | $475 |
| Regeneron Healthcare Solutions, Inc. | 9 | $456 |
| Harmony Biosciences LLC | 6 | $343 |
| Sanofi | 12 | $301 |
| United Therapeutics Corporation | 8 | $236 |
| Pulmonx Corporation | 3 | $216 |
| Insmed, Inc. | 7 | $189 |
| Tepha Inc | 1 | $163 |
| Intuitive Surgical | 1 | $132 |
| Electromed, Inc. | 7 | $132 |
| Abiomed | 1 | $125 |
| Novo Nordisk | 6 | $120 |
| Amgen | 4 | $101 |
| Sunovion Pharmaceuticals Inc. | 4 | $82 |
| Advanced Respiratory, Inc | 4 | $72 |
| Lilly USA, LLC | 3 | $62 |
| Shionogi Inc | 2 | $62 |
| Philips North America LLC | 2 | $44 |
| Paratek Pharmaceuticals, Inc. | 2 | $34 |
| Radius Health, Inc. | 1 | $28 |
| Gilead | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Pfizer | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$393,623 in reported general payments places this provider in the 95th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 563 | $395,265 |
| AdempasRiociguat | 28 | $390,397 |
| OfevNintedanib Esylate | 28 | $352,104 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 258 | $133,876 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 186 | $127,155 |
| Ambrisentan | 24 | $119,256 |
| Fasenra PenBenralizumab | 17 | $92,963 |
| Breo ElliptaFluticasone/Vilanterol | 174 | $77,615 |
| CreonLipase/Protease/Amylase | 65 | $75,131 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 150 | $74,589 |
| JardianceEmpagliflozin | 83 | $54,815 |
| NucalaMepolizumab | 13 | $47,981 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 84 | $43,682 |
| Roflumilast | 339 | $42,339 |
| EliquisApixaban | 49 | $30,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta | $216,453 | $672,7821,050 claims |
| Boehringer IngelheimOfev, Combivent Respimat, Jardiance, Stiolto Respimat, Spiriva Respimat | $28,968 | $549,302379 claims |
| BayerAdempas | $11,225 | $390,39728 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $105,032 | $135,339201 claims |
| AbbVieCreon, Restasis, Linzess, Lumigan | $9,971 | $110,769131 claims |
| PfizerEliquis | $14 | $30,41149 claims |
| MerckJanuvia, Belsomra | $999 | $19,96739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Monterey Park
- Rafael LupercioRedding$14.6M
- Timothy AlbertsonSacramento$7.6M
- Carolyn CalfeeSan Francisco$5M
- Bassam YaghmourOrange$4.4M
- Cedric Franklin RutlandRiverside$3.2M
- Alex HakimLos Angeles$946K
- Praveen AkuthotaSan Diego$841K
- Wael El MaraachliSan Diego$751K
- Stephen RuossStanford$635K
- Bryon QuickOakland$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.